DaVita HealthCare Partners (NYSE:DVA) has been given a $70.00 price objective by analysts at SunTrust Banks in a research report issued to clients and investors on Thursday. The firm currently has a “hold” rating on the stock. SunTrust Banks’ price target points to a potential upside of 4.04% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on DVA. KeyCorp reissued a “hold” rating on shares of DaVita HealthCare Partners in a research report on Wednesday. Raymond James Financial raised DaVita HealthCare Partners from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $65.00 to $84.00 in a research report on Thursday. Robert W. Baird reissued a “hold” rating and issued a $63.00 price objective on shares of DaVita HealthCare Partners in a research report on Friday, November 10th. Royal Bank Of Canada reduced their price objective on DaVita HealthCare Partners from $64.00 to $60.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 8th. Finally, Zacks Investment Research cut DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $69.88.

DaVita HealthCare Partners (DVA) traded up $0.14 on Thursday, hitting $67.28. The stock had a trading volume of 140,266 shares, compared to its average volume of 1,650,155. DaVita HealthCare Partners has a 12 month low of $52.51 and a 12 month high of $70.16. The company has a quick ratio of 1.35, a current ratio of 1.40 and a debt-to-equity ratio of 1.79. The company has a market capitalization of $13,094.83, a PE ratio of 19.77, a price-to-earnings-growth ratio of 13.95 and a beta of 0.97.

DaVita HealthCare Partners (NYSE:DVA) last posted its quarterly earnings data on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.13). DaVita HealthCare Partners had a net margin of 3.40% and a return on equity of 13.31%. The business had revenue of $3.92 billion during the quarter, compared to the consensus estimate of $3.91 billion. During the same period in the prior year, the company posted $0.95 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. equities research analysts anticipate that DaVita HealthCare Partners will post 3.42 EPS for the current fiscal year.

DaVita HealthCare Partners declared that its Board of Directors has approved a stock repurchase program on Tuesday, October 10th that permits the company to repurchase $1.50 billion in shares. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Hedge funds have recently modified their holdings of the stock. Rhumbline Advisers lifted its position in DaVita HealthCare Partners by 4.4% in the third quarter. Rhumbline Advisers now owns 321,155 shares of the company’s stock worth $19,073,000 after purchasing an additional 13,471 shares during the period. Riverhead Capital Management LLC lifted its position in DaVita HealthCare Partners by 10.6% in the second quarter. Riverhead Capital Management LLC now owns 112,506 shares of the company’s stock worth $7,286,000 after purchasing an additional 10,775 shares during the period. Founders Capital Management LLC lifted its position in DaVita HealthCare Partners by 2.3% in the third quarter. Founders Capital Management LLC now owns 95,939 shares of the company’s stock worth $5,698,000 after purchasing an additional 2,115 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH lifted its position in DaVita HealthCare Partners by 1,987.3% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock worth $2,448,000 after purchasing an additional 39,746 shares during the period. Finally, Speece Thorson Capital Group Inc. lifted its position in DaVita HealthCare Partners by 14.5% in the third quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock worth $19,075,000 after purchasing an additional 40,667 shares during the period. 85.32% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/07/davita-healthcare-partners-dva-price-target-raised-to-70-00.html.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.